Lilly Withdraws Application For Additional U.S. Indication For Cymbalta(R) For Chronic Pain

Link:

Eli Lilly and Company (NYSE: LLY) has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta(R) (duloxetine HCl) for the management of chronic pain. Lilly plans to resubmit the application in the first half of 2009, adding data from a recently completed positive study in chronic osteoarthritis pain of the knee.

Translate into: cs pl ru de ja nl es ar pt fr el it ko tr no fi hu sv ro hi bg et lt lt sk tl iw hr id ca lv sl sr uk vi
Link: http://www.medicalnewstoday.com/articles/131230.php
Complete RSS
<<< Back

Lilly Withdraws Application For Additional U.S. Indication For Cymbalta(R) For Chronic Pain - témata

Withdraws, Application, For, Additional, Indication, Cymbalta(R), Chronic, Pain, Lilly Withdraws Application For Additional U.S. Indication For Cymbalta(R) For Chronic Pain , Lilly, Company, (NYSE:, LLY), New, Drug, (sNDA), Food, Administration, (FDA), (duloxetine, HCl), 2009, Eli Lilly, Company (NYSE:, New Drug Application (sNDA), U.S. Food, Drug Administration (FDA), Cymbalta(R) (duloxetine HCl), 2009,, Lilly Withdraws Application For Additional U.S. Indication For Cymbalta(R) For Chronic Pain,

Lilly Withdraws Application For Additional U.S. Indication For Cymbalta(R) For Chronic Pain

Lilly Withdraws Application For Additional U.S. Indication For Cymbalta(R) For Chronic Pain - témata

Podobné zprávy

RSS sources

Your own sources

Public sources